ClinicalTrials.gg
CompletedNCT03549871ATLAS-PPXUpdated Feb 6, 2023Results posted

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

A Phase 3 interventional study of Fitusiran and BPA prophylaxis in Hemophilia, sponsored by Genzyme, a Sanofi Company. Completed at 35 sites in 15 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-02-06.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
5th of 10
80 · median 70
Started
2018
with 2 others
Phase 3
6 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
6 of 10
Genzyme, a Sanofi Company

Among the 10 studies testing fitusiran in Hemophilia A, this one is the 5th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 5th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

Primary Objective:

To characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis.

Secondary Objectives:

  • To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis:
  • the frequency of spontaneous bleeding episodes
  • the frequency of joint bleeding episodes
  • health related quality of life (HRQOL) in participants greater than or equal to (>=) 17 years of age
  • To characterize the frequency of bleeding episodes during the onset and treatment periods in participants receiving fitusiran.
  • To characterize the safety and tolerability of fitusiran.
  • To characterize the annualized weight-adjusted consumption of factor/BPA while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis.
Read the detailed description

The estimated total time on study, inclusive of Screening, for each participant was up to 15 months for participants who were enrolled in the extension study except for participants in the subgroup of Cohort A, for whom it was up to 9 months. The estimated total time on study was up to 21 months (up to 15 months in participants in the subgroup of Cohort A) in participants who did not enroll in the extension study due to the requirement for an additional up to 6 months of follow-up for monitoring of antithrombin (AT) levels.

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males, >=12 years of age.
  • Severe hemophilia A or B (as evidenced by a central laboratory measurement at screening or documented medical record evidence of FVIII less than (\<) 1 percent (%) or FIX level less than or equal to (\<=) 2%).
  • A minimum of 2 bleeding episodes required BPA treatment within the last 6 months prior to screening for participants with inhibitory antibodies to factor VIII or factor IX (Cohort A). A minimum of 1 bleeding episode required factor treatment within the last 12 months prior to screening for participants without inhibitory antibodies to factor VIII or factor IX (Cohort B).
  • Met either the definition of inhibitor or non-inhibitor participant as below:
  • Inhibitor: Use of BPAs for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met one of the following Nijmegen-modified Bethesda assay results criteria:
  • Inhibitor titer of >=0.6 Bethesda Unit per milliliter (BU/mL) at screening, or
  • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of 2 consecutive titers >=0.6 BU/mL, or
  • Inhibitor titer of \<0.6 BU/mL at screening with medical record evidence of anamnestic response
  • The subgroup of participants in Cohort A participants might additionally meet the following criteria to be eligible to start treatment with fitusiran directly after the screening period:

    • Hemophilia B with inhibitory antibody to Factor IX as defined above
    • Not responding adequately to BPA treatment (historical ABR >=20) prior to enrollment
    • In the opinion of the Investigator, with approval of Sponsor Medical Monitor, 6-month BPA prophylaxis period should be omitted.
  • Non-inhibitor: Use of factor concentrates for prophylaxis and for any bleeding episodes for at least the last 6 months prior to screening, and met each of the following criterion:
  • Nijmegen-modified Bethesda assay inhibitor titer of \<0.6 BU/mL at screening and
  • No use of BPAs to treat bleeding episodes for at least the last 6 months prior to screening and
  • No history of immune tolerance induction therapy within the past 3 years prior to screening.
  • Documented prophylactic treatment with factor concentrates or BPAs for the treatment of hemophilia A or B for at least 6 months prior to screening.
  • Adherent to the prescribed prophylactic therapy for at least 6 months prior to screening per Investigator assessment.
  • Willed and complied with the study requirements and to provide written and assent.

Exclusion criteria

Exclusion Criteria:

  • Known co-existing bleeding disorders other than hemophilia A or B.
  • AT activity \<60% at screening.
  • Co-existing thrombophilic disorder.
  • liver disease.
  • Active virus infection.
  • Acute or chronic virus infection.
  • positive with a of \<200 cells per microliter.
  • History of arterial or venous thromboembolism.
  • Inadequate renal function.
  • History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc).
  • History of intolerance to subcutaneous injection(s).
  • Any other conditions or comorbidities that made the participant unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Fitusiran

    Cohort A \[inhibitor\]: participants with severe hemophilia A/B and inhibitory antibodies to coagulation factor VIII (FVIII)/factor IX (FIX) previously received BPA prophylaxis. Cohort B \[non-inhibitor\]: participants with severe hemophilia A/B without inhibitory antibodies to FVIII/FIX previously received factor prophylaxis. Participants from both cohorts was enrolled into 6-month factor/BPA prophylaxis period and continued their pre-study, regularly scheduled prophylaxis regimen with factor/BPAs. This period could be skipped by subgroup of Cohort A (hemophilia B with inhibitors to FIX and historical annualized bleeding rate \[ABR\] \>=20) that started directly with fitusiran. Post completing factor/BPA prophylaxis period, participants entered 7-month fitusiran treatment period (1-month onset+6-month efficacy) followed by AT follow-up/roll-over into LTE15174 (NCT03754790). Throughout study, participants could receive on-demand treatment for breakthrough BE with factor/BPAs, as appropriate.

    Drug: Fitusiran · Drug: BPA prophylaxis · Drug: Factor (FVIII or FIX) prophylaxis

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • DrugBPA prophylaxis

    Pharmaceutical form: solution for injection Route of administration: Intravenous

  • DrugFactor (FVIII or FIX) prophylaxis

    Pharmaceutical form: solution for injection Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Estimated Annualized Bleeding Rate (ABR)

    Bleeding episodes (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/total number of days in the respective period\*365.25. Estimated data were derived by using repeated measures negative binomial (NB) regression model.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  2. Observed Annualized Bleeding Rate (ABR)

    A bleeding episode (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as 1 BE towards ABR. Any bleeding that began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/number of days in the respective period \*365.25.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

Secondary outcomes

  1. Estimated Annualized Spontaneous Bleeding Rate

    BE: any occurrence of hemorrhage that might require administration of factor/BPA infusion. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. Spontaneous BE: BE occurrence for no apparent/known reason, particularly into joints, muscles, and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data was derived using repeated measures NB regression model.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  2. Observed Annualized Spontaneous Bleeding Rate

    BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Spontaneous BE: bleeding event occurred for no apparent or known reason, particularly into joints, muscles and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  3. Estimated Annualized Joint Bleeding Rate

    BE: any hemorrhage that required administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection to treat BE at that location was considered part of original BE; counted as 1 BE towards ABR. Bleeding after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint ("aura") + increasing swelling/warmth over joint skin, increasing pain/progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data were derived by using repeated measures NB regression model.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  4. Observed Annualized Joint Bleeding Rate

    BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint (aura) increasing swelling/warmth over joint skin, increasing pain or progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of joint BE/number of days in respective period\*365.25.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  5. Change in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period

    Haem-A-QoL: participant-reported questionnaire for adults aged \>=17 years with hemophilia and comprised of 46 items covering 10 domains. Physical health domain (PHD) is assessed with 5 items rated on 5-point Likert scale: never, rarely, sometimes, often or all the time. Raw score for PHD were transformed to scale ranged from 0 to 100, where lower scores = better physical health. Least square (LS) mean and 95% confidence interval (CI) by mixed model for repeated measure (MMRM) analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.

    Time frame: Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period

  6. Change in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period

    Haem-A-QoL: questionnaire for adults aged \>= 17 years with hemophilia; and comprised of 46 items covering 10 domains: physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality. Items were rated on 5-point Likert scale: never, rarely, sometimes, often or all time. Domain raw score was transformed to scale ranged from 0 to 100, where lower scores=better health. LS mean \& 95% CI by MMRM analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.

    Time frame: Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period

  7. Estimated Annualized Bleeding Rate in the Fitusiran Onset Period

    BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Estimated ABR and 95% CI was derived by using repeated measures NB regression model with logarithm of duration (years) that each participant spends in 1-Month fitusiran onset period matching BE data being analyzed as offset variable. ABR = total number of qualifying BE/number of days in respective period \*365.25.

    Time frame: Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest

  8. Observed Annualized Bleeding Rate in the Fitusiran Onset Period

    BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and was counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in the 1-month onset period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in 1-month onset period and excluded any bleeding events in period of intercurrent events.

    Time frame: Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest

  9. Estimated Annualized Bleeding Rate in the Fitusiran Treatment Period

    BE: defined as any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in the period of intercurrent events. ABR = total number of qualifying BE/number of days in respective period \*365.25.

    Time frame: From Day 1 up to Day 190

  10. Observed Annualized Bleeding Rate in the Fitusiran Treatment Period

    BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original bleeding event and was counted as one BE towards ABR. Any bleeding that began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in treatment period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in period of intercurrent events.

    Time frame: from Day 1 up to Day 190

  11. Cohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates)

    Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: \[Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period\]\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agent: aPCC (unit per kilogram \[U/kg\]) were reported.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  12. Cohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa)

    Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: rFVIIa (unit: micrograms per kg \[mcg/kg\]) were reported. Combined data of annualized weight-adjusted BPA consumption (mcg/kg) for both treated bleeds and prophylaxis purpose were reported in this outcome measure.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

  13. Cohort B: Annualized Weight-adjusted Consumption of Factor

    Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: FVIII and FIX (unit: international Units \[IU\] per kg \[IU/kg\]) were reported.

    Time frame: Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest

07

Results

Posted Feb 6, 2023

Participant flow

Study was conducted at 35 active sites in 15 countries. Total of 99 participants were screened from 25 July 2018 to 19 March 2021, of which 19 were screen failure due to not meeting eligibility criteria. Study had 2 main periods: 6-month factor/bypassing agent (BPA) prophylaxis period \& 7-month fitusiran treatment period (1-month onset and 6-month fitusiran efficacy period).

Factor/BPA Prophylaxis: Day -168 to -1
Participant flow — Factor/BPA Prophylaxis: Day -168 to -1
MilestoneCohort A: InhibitorCohort B: Non-inhibitor
Started3050
Started directly with fitusiran20
Started with factor or bpa prophylaxis2850
Completed2346
Not completed74
Withdrew: Withdrawal by subject02
Withdrew: Adverse event10
Withdrew: Parent withdrew consent10
Withdrew: Switched to treatment not per protocol40
Withdrew: Related to coronavrus disease 201910
Withdrew: Did not meet trial eligibility02
Fitusiran Treatment: Day 1 to Day 190
Participant flow — Fitusiran Treatment: Day 1 to Day 190
MilestoneCohort A: InhibitorCohort B: Non-inhibitor
Started2346
Received 80mg qm & part of safety analysis set 1 (sas 1)2146
Received 50 mg q2m & part of safety analysis set 2 (sas 2)20
Efficacy analysis set 1 (eas 1)1946
Efficacy analysis set 2 (eas 2)20
Completed1737
Not completed69
Withdrew: Withdrawal by subject10
Withdrew: More than 1 antithrombin (at) measurement less than 15%10
Withdrew: Study drug on hold45
Withdrew: Participant's decision02
Withdrew: Adverse event02

Outcome measures

PrimaryEstimated Annualized Bleeding Rate (ABR)

Bleeding episodes (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/total number of days in the respective period\*365.25. Estimated data were derived by using repeated measures negative binomial (NB) regression model.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Number · episodes per participant per year
Estimated Annualized Bleeding Rate (ABR)
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Estimated Annualized Bleeding Rate (ABR)7.482 (5.520 to 10.141)2.908 (1.727 to 4.898)
Statistical analysis
  • Overall Factor/BPA Prophylaxis Period vs Overall Fitusiran 80 mg Efficacy Period · Repeated measures NB regression model · p = =0.0008 (The threshold for significance was \<0.05.) · Abr ratio: 0.389 · 95% CI 0.224 to 0.675
PrimaryObserved Annualized Bleeding Rate (ABR)

A bleeding episode (BE): any occurrence of hemorrhage might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as 1 BE towards ABR. Any bleeding that began after 72 hours of last injection at that location was considered as a new event. ABR = total number of qualifying BE/number of days in the respective period \*365.25.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · episodes per participant per year
Observed Annualized Bleeding Rate (ABR)
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Observed Annualized Bleeding Rate (ABR)7.56 ± 9.493.19 ± 7.75
SecondaryEstimated Annualized Spontaneous Bleeding Rate

BE: any occurrence of hemorrhage that might require administration of factor/BPA infusion. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours of last injection at that location was considered as a new event. Spontaneous BE: BE occurrence for no apparent/known reason, particularly into joints, muscles, and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data was derived using repeated measures NB regression model.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Number · episodes per participant per year
Estimated Annualized Spontaneous Bleeding Rate
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Estimated Annualized Spontaneous Bleeding Rate5.002 (3.424 to 7.305)2.222 (1.190 to 4.152)
Statistical analysis
  • Overall Factor/BPA Prophylaxis Period vs Overall Fitusiran 80 mg Efficacy Period · Abr ratio: 0.444 · 95% CI 0.234 to 0.842
SecondaryObserved Annualized Spontaneous Bleeding Rate

BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Spontaneous BE: bleeding event occurred for no apparent or known reason, particularly into joints, muscles and soft tissues. ABR = total number of qualifying BE/number of days in respective period \*365.25.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · episodes per participant per year
Observed Annualized Spontaneous Bleeding Rate
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Observed Annualized Spontaneous Bleeding Rate5.09 ± 7.932.51 ± 7.33
SecondaryEstimated Annualized Joint Bleeding Rate

BE: any hemorrhage that required administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection to treat BE at that location was considered part of original BE; counted as 1 BE towards ABR. Bleeding after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint ("aura") + increasing swelling/warmth over joint skin, increasing pain/progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of qualifying BE/number of days in respective period \*365.25. Estimated data were derived by using repeated measures NB regression model.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Number · episodes per participant per year
Estimated Annualized Joint Bleeding Rate
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Estimated Annualized Joint Bleeding Rate5.282 (3.647 to 7.651)2.564 (1.440 to 4.566)
Statistical analysis
  • Overall Factor/BPA Prophylaxis Period vs Overall Fitusiran 80 mg Efficacy Period · Abr ratio: 0.485 · 95% CI 0.259 to 0.910
SecondaryObserved Annualized Joint Bleeding Rate

BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. Joint BE: characterized by unusual sensation in joint (aura) increasing swelling/warmth over joint skin, increasing pain or progressive loss of range of motion/difficulty in limb use compared to Baseline. ABR = total number of joint BE/number of days in respective period\*365.25.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · episodes per participant per year
Observed Annualized Joint Bleeding Rate
episodes per participant per yearOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Efficacy Period
Observed Annualized Joint Bleeding Rate5.35 ± 8.192.82 ± 7.54
SecondaryChange in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period

Haem-A-QoL: participant-reported questionnaire for adults aged \>=17 years with hemophilia and comprised of 46 items covering 10 domains. Physical health domain (PHD) is assessed with 5 items rated on 5-point Likert scale: never, rarely, sometimes, often or all the time. Raw score for PHD were transformed to scale ranged from 0 to 100, where lower scores = better physical health. Least square (LS) mean and 95% confidence interval (CI) by mixed model for repeated measure (MMRM) analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.

Time frame:
Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period
Reported as:
Least squares mean · score on a scale
Change in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period
score on a scaleOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Treatment Period
Change in Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QOL) Physical Health Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period-6.00 (-10.19 to -1.81)-9.60 (-15.35 to -3.84)
SecondaryChange in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period

Haem-A-QoL: questionnaire for adults aged \>= 17 years with hemophilia; and comprised of 46 items covering 10 domains: physical health, feelings, view of yourself, sports and leisure, work and school, dealing with hemophilia, treatment, future, family planning, partnership and sexuality. Items were rated on 5-point Likert scale: never, rarely, sometimes, often or all time. Domain raw score was transformed to scale ranged from 0 to 100, where lower scores=better health. LS mean \& 95% CI by MMRM analysis with robust sandwich covariance matrix: change from Month -6 to Day 1 and to Month 7 as response variable; period (factor/BPA prophylaxis \& fitusiran treatment) \& Baseline score (Month -6) as fixed effects.

Time frame:
Month -6 of Factor or BPA prophylaxis period (Baseline), Day 1 (Month 1) and Month 7 of fitusiran treatment period
Reported as:
Least squares mean · score on a scale
Change in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period
score on a scaleOverall Factor/BPA Prophylaxis PeriodOverall Fitusiran 80 mg Treatment Period
Change in Haemophilia Quality of Life Questionnaire for Adults Total Score in the Fitusiran Treatment Period and the Factor or BPA Prophylaxis Period-3.07 (-5.56 to -0.58)-7.62 (-10.26 to -4.98)
SecondaryEstimated Annualized Bleeding Rate in the Fitusiran Onset Period

BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered part of original BE and was counted as 1 BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Estimated ABR and 95% CI was derived by using repeated measures NB regression model with logarithm of duration (years) that each participant spends in 1-Month fitusiran onset period matching BE data being analyzed as offset variable. ABR = total number of qualifying BE/number of days in respective period \*365.25.

Time frame:
Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest
Reported as:
Number · episodes per participant per year
Estimated Annualized Bleeding Rate in the Fitusiran Onset Period
episodes per participant per yearOverall Fitusiran 80 mg 1-Month Onset Period
Estimated Annualized Bleeding Rate in the Fitusiran Onset Period5.419 (3.716 to 7.901)
SecondaryObserved Annualized Bleeding Rate in the Fitusiran Onset Period

BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time: time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and was counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in the 1-month onset period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in 1-month onset period and excluded any bleeding events in period of intercurrent events.

Time frame:
Day 1 up to Day 28 or up to the last day of bleeding follow up (any day up to Day 28), whichever was earliest
Reported as:
Mean · episodes per participant per year
Observed Annualized Bleeding Rate in the Fitusiran Onset Period
episodes per participant per yearOverall Fitusiran 80 mg 1-Month Onset Period
Observed Annualized Bleeding Rate in the Fitusiran Onset Period5.42 ± 8.28
SecondaryEstimated Annualized Bleeding Rate in the Fitusiran Treatment Period

BE: defined as any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original BE and counted as one BE towards ABR. Bleeding began after 72 hours from last injection at that location was considered as new event. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in the period of intercurrent events. ABR = total number of qualifying BE/number of days in respective period \*365.25.

Time frame:
From Day 1 up to Day 190
Reported as:
Number · episodes per participant per year
Estimated Annualized Bleeding Rate in the Fitusiran Treatment Period
episodes per participant per yearOverall Fitusiran 80 mg Treatment Period
Estimated Annualized Bleeding Rate in the Fitusiran Treatment Period3.317 (2.111 to 5.211)
SecondaryObserved Annualized Bleeding Rate in the Fitusiran Treatment Period

BE: any occurrence of hemorrhage that might require administration of factor/BPA. BE start time was time at which 1st BE symptoms develop; bleeding/any symptoms at same location that occurred within 72 hours of last injection used to treat BE at that location was considered a part of original bleeding event and was counted as one BE towards ABR. Any bleeding that began after 72 hours from last injection at that location was considered as a new event. ABR= total number of qualifying BE/number of days in treatment period \*365.25. Analysis was based on on-treatment strategy which included all treated bleeding events in fitusiran period and excluded any bleeding events in period of intercurrent events.

Time frame:
from Day 1 up to Day 190
Reported as:
Mean · episodes per participant per year
Observed Annualized Bleeding Rate in the Fitusiran Treatment Period
episodes per participant per yearOverall Fitusiran 80 mg Treatment Period
Observed Annualized Bleeding Rate in the Fitusiran Treatment Period3.48 ± 6.98
SecondaryCohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates)

Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: \[Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period\]\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agent: aPCC (unit per kilogram \[U/kg\]) were reported.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · U/kg per participant per year
Cohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates)
U/kg per participant per yearBPA Prophylaxis: Cohort: A InhibitorFitusiran 80 mg Prophylaxis: Cohort A: Inhibitor
Cohort A: Annualized Weight-adjusted Consumption of BPA (Activated Prothrombin Complex Concentrates)7912.7 ± 5507.639.7 ± 87.0
SecondaryCohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa)

Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: rFVIIa (unit: micrograms per kg \[mcg/kg\]) were reported. Combined data of annualized weight-adjusted BPA consumption (mcg/kg) for both treated bleeds and prophylaxis purpose were reported in this outcome measure.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · mcg/kg per participant per year
Cohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa)
mcg/kg per participant per yearBPA Prophylaxis: Cohort: A InhibitorFitusiran 80 mg Prophylaxis: Cohort A: Inhibitor
Cohort A: Annualized Weight-adjusted Consumption of BPA (Recombinant Factor VIIa)18895.8 ± 14081.9168.8 ± 290.8
SecondaryCohort B: Annualized Weight-adjusted Consumption of Factor

Annualized weight-adjusted BPA consumption was calculated for each participant during prophylaxis period as: (Sum of BPA dose per body weight received during corresponding period/number of days in corresponding period)\*365.25. In this outcome measure, data of annualized weight-adjusted consumption of BPA agents: FVIII and FIX (unit: international Units \[IU\] per kg \[IU/kg\]) were reported.

Time frame:
Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest
Reported as:
Mean · IU/kg per participant per year
Cohort B: Annualized Weight-adjusted Consumption of Factor
IU/kg per participant per yearFactor Prophylaxis: Cohort B: Non-inhibitorFitusiran 80 mg Prophylaxis: Cohort B: Non-inhibitor
FVIII3396.9 ± 1144.560.7 ± 148.3
FIX3175.5 ± 961.317.8 ± 56.1

Adverse events

Collected over Factor/BPA prophylaxis period: from Day -168 to Day -1; Fitusiran 80 mg QM/50 mg Q2M period: from Day 1 of fitusiran treatment period (i.e., 1 month onset+ 6 months efficacy) until AT follow up (i.e. up to 21 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: SAS 1 - BPA Prophylaxis0/19 (0%)5/19 (26.3%)10/19 (52.6%)
Cohort A: SAS 1 - Fitusiran 80 mg QM0/21 (0%)5/21 (23.8%)13/21 (61.9%)
Cohort B: SAS 1 - Factor Prophylaxis0/46 (0%)0/46 (0%)9/46 (19.6%)
Cohort B: SAS 1 - Fitusiran 80 mg QM0/46 (0%)4/46 (8.7%)28/46 (60.9%)
Overall: SAS 1 - Factor/BPA Prophylaxis0/65 (0%)5/65 (7.7%)19/65 (29.2%)
Overall: SAS 1 - Fitusiran 80 mg QM0/67 (0%)9/67 (13.4%)41/67 (61.2%)
Cohort A: SAS 2 - BPA Prophylaxis0/2 (0%)1/2 (50%)1/2 (50%)
Cohort A: SAS 2 - Fitusiran 50 mg Q2M0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventCohort A: SAS 1 - BPA ProphylaxisCohort A: SAS 1 - Fitusiran 80 mg QMCohort B: SAS 1 - Factor ProphylaxisCohort B: SAS 1 - Fitusiran 80 mg QMOverall: SAS 1 - Factor/BPA ProphylaxisOverall: SAS 1 - Fitusiran 80 mg QMCohort A: SAS 2 - BPA ProphylaxisCohort A: SAS 2 - Fitusiran 50 mg Q2M
HaemarthrosisMusculoskeletal and connective tissue disorders1/190/210/460/461/650/671/20/2
Covid-19 PneumoniaInfections and infestations0/190/210/460/460/650/670/21/2
Haemophilic ArthropathyMusculoskeletal and connective tissue disorders2/191/210/461/462/652/670/20/2
Muscle HaemorrhageMusculoskeletal and connective tissue disorders1/190/210/460/461/650/670/20/2
GastroenteritisInfections and infestations1/190/210/460/461/650/670/20/2
FallInjury, poisoning and procedural complications0/191/210/460/460/651/670/20/2
Femur FractureInjury, poisoning and procedural complications0/191/210/460/460/651/670/20/2
Pancreatitis AcuteGastrointestinal disorders0/191/210/460/460/651/670/20/2
Central Venous Catheter RemovalSurgical and medical procedures0/191/210/460/460/651/670/20/2
CholelithiasisHepatobiliary disorders0/191/210/460/460/651/670/20/2
Most frequent other events
Showing 10 of 37
Most frequent other events
EventCohort A: SAS 1 - BPA ProphylaxisCohort A: SAS 1 - Fitusiran 80 mg QMCohort B: SAS 1 - Factor ProphylaxisCohort B: SAS 1 - Fitusiran 80 mg QMOverall: SAS 1 - Factor/BPA ProphylaxisOverall: SAS 1 - Fitusiran 80 mg QMCohort A: SAS 2 - BPA ProphylaxisCohort A: SAS 2 - Fitusiran 50 mg Q2M
ToothacheGastrointestinal disorders0/191/210/461/460/652/670/22/2
Fibrin D Dimer IncreasedInvestigations0/193/210/462/460/655/670/21/2
Lymphocyte Count IncreasedInvestigations0/190/210/460/460/650/671/20/2
Neutrophil Count DecreasedInvestigations0/190/210/460/460/650/671/20/2
White Blood Cell Count DecreasedInvestigations0/190/210/460/460/650/671/20/2
HaemorrhoidsGastrointestinal disorders0/190/210/460/460/650/671/20/2
Alanine Aminotransferase IncreasedInvestigations1/193/210/4615/461/6518/670/20/2
Upper Respiratory Tract InfectionInfections and infestations3/194/211/462/464/656/670/20/2
NasopharyngitisInfections and infestations0/191/211/467/461/658/670/20/2
FallInjury, poisoning and procedural complications2/190/210/460/462/650/670/20/2

Baseline characteristics

Baseline analysis population included all completed participants from BPA/factor prophylaxis period + 2 participants from Cohort A subgroup who directly enrolled to fitusiran treatment period.

Age, Continuous
Age, Continuous(years)Cohort A: InhibitorCohort B: Non-inhibitorTotal Title
Mean27.7 ± 15.923.5 ± 7.324.9 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: InhibitorCohort B: Non-inhibitorTotal Title
Female000
Male234669
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: InhibitorCohort B: Non-inhibitorTotal Title
American Indian or Alaska Native000
Asian41721
Native Hawaiian or Other Pacific Islander000
Black or African American101
White182745
More than one race000
Unknown or Not Reported022
08

Study locations

35 sites
  • Investigational Site Number 0139
    Los Angeles, California 90027, United States
  • Investigational Site Number 6104
    Prahran, 3181, Australia
  • Investigational Site Number 8604
    Beijing, 100045, China
  • Investigational Site Number 4501
    Copenhagen, 2100, Denmark
  • Investigational Site Number 3303
    Lyon, 69677, France
  • Investigational Site Number 5301
    Crumlin, 12, Ireland
  • Investigational Site Number 9701
    Ramat-Gan, 52621, Israel
  • Investigational Site Number 3902
    Milano, 20122, Italy
  • Investigational Site Number 8101
    Nagoya, Japan
  • Investigational Site Number 8102
    Nishinomiya, Japan
  • Investigational Site Number 8104
    Saitama, Japan
  • Investigational Site Number 8109
    Tokyo, Japan
  • Investigational Site Number 8201
    Busan, 602-739, Korea, Republic of
  • Investigational Site Number 8202
    Daejeon, 35233, Korea, Republic of
  • Investigational Site Number 8204
    Seoul, 3722, Korea, Republic of
  • Investigational Site Number 6004
    Ampang, 68000, Malaysia
  • Investigational Site Number 6002
    Johor Bahru, 80100, Malaysia
  • Investigational Site Number 6003
    Kota Kinabalu, 88586, Malaysia
  • Investigational Site Number 5201
    San Pablo, Mexico
  • Investigational Site Number 9002
    Adana, ?01130, Turkey
  • Investigational Site Number 9001
    Ankara, 06100, Turkey
  • Investigational Site Number 9004
    Antalya, 07059, Turkey
  • Investigational Site Number 9008
    Gaziantep, 27100, Turkey
  • Investigational Site Number 9005
    Istanbul, 34093, Turkey
  • Investigational Site Number 9010
    İzmir, 35040, Turkey
  • Investigational Site Number 9003
    Izmir, TR-35100, Turkey
  • Investigational Site Number 9009
    Kayseri, 38039, Turkey
  • Investigational Site Number 9006
    Samsun, 55200, Turkey
  • Investigational site number 9013
    Van, 65080, Turkey
  • Investigational Site Number 8003
    Kyiv, ?01135, Ukraine
  • Investigational Site Number 8002
    Lviv, 79044, Ukraine
  • Investigational Site Number 4402
    Glasgow, G4 0SF, United Kingdom
  • Investigational Site Number 4407
    London, E1 2ES, United Kingdom
  • Investigational Site Number 4403
    London, NW3 2QG, United Kingdom
  • Investigational Site Number 4401
    London, SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jan 2022, 41 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 41 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jun 8, 2018
StartActual
Jul 25, 2018
Primary completionActual
Jan 20, 2022
CompletionActual
Mar 25, 2022
Results first posted
Feb 6, 2023
Last update
Feb 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03549871
Responsible party
Sponsor
First posted
Jun 8, 2018
Start date
Jul 25, 2018
Primary completion
Jan 20, 2022
Completion
Mar 25, 2022
Results posted
Feb 6, 2023
Last update
Feb 6, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion